Diligence memo · auto-generated · as of July 2, 2026

Cequent Pharmaceuticals Inc

Cequent Pharmaceuticals Inc looks fair against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Cequent Pharmaceuticals Inc operates in Pharmaceuticals, based in CAMBRIDGE.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Cequent Pharmaceuticals Inc has raised $2.7M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).

Largest single filing: $2.7M on 2009-10-16.

Most recent recorded round closed around 2009-10-16.

Valuation (modeled)modeled

Provath models Cequent Pharmaceuticals Inc at approximately $101M (range $2.0M–$792M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.25× the median modeled value of Seed Pharmaceuticals companies in 2007–2009 (25 peers) — value vs value, same stage and era. Within the normal band (125% of peer median) for its niche.

Financing rhythm & timingmixed

Last raise 16.7 yr ago; this sector typically re-raises about every 13 months.

Only one round on record and long silent — often defunct, acquired, or gone quiet.

Comparablesmixed

Capital scale ranks ahead of 32% of Pharmaceuticals peers (1613 compared).

Modeled value ranks above 55% of those peers.

Closest niche peers: Sequoia Pharmaceuticals Inc, Spring Pharmaceuticals, LLC, Oceana Therapeutics, Inc., Supergen Inc, Archer Pharmaceuticals, Inc..

Peoplefiled

7 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.